Mechanism
Sermorelin is the first 29 amino acids of natural growth-hormone-releasing hormone (GHRH, which is 44 residues) — the shortest fragment that keeps full biological activity. It works upstream of growth hormone itself, nudging the pituitary rather than replacing the hormone.
| Mechanism | Detail |
|---|---|
| GHRH receptor agonism | Binds the GHRH receptor on pituitary somatotrophs, stimulating synthesis and pulsatile release of the body’s own growth hormone. |
| Preserves feedback loops | Because it acts on the pituitary, output stays subject to somatostatin and IGF-1 negative feedback — a built-in ceiling that direct GH injection bypasses. |
| Pulsatile, night-weighted release | Amplifies natural GH pulses, which is why compounded protocols favor bedtime dosing to align with nocturnal secretion. |
| Short pharmacokinetics | A ~10–20 minute half-life means the signal is brief and physiologic — the basis for its historical use as a pituitary function probe. |
Evidence Summary
Sermorelin is unusual in the peptide world: it has a real regulatory and clinical record, not just anecdotes. The catch is that most rigorous data address pediatric growth-hormone deficiency and diagnostic testing — not the adult anti-aging uses that drive today’s compounded market.
| Research Area | Evidence | Study Type | Notes |
|---|---|---|---|
| Pediatric GH deficiency (Rx) | Increased growth velocity in children | Human / RCT | FDA-approved use as Geref; a distinct population from adult wellness users. |
| Pituitary GH reserve (diagnosis) | Assesses somatotroph capacity | Human / clinical | Well-characterized diagnostic application (Geref Diagnostic). |
| Adult GH/IGF-1 elevation | Raises GH and IGF-1 in adults | Human / small | Biomarker movement is real; clinical outcomes less established. |
| Body composition & aging | Claims rest on extrapolation | Indirect | The gap between marketing and controlled adult data is wide. |
| Long-term safety (healthy adults) | No large long-duration trials | Absent | Legacy safety data come from supervised pediatric and diagnostic use. |
| Human clinical trials | Genuine trial history exists | Human | More real evidence than most peptides — just not for how it is mostly used now. |
Divergence — What This Means
A real FDA pedigree, earned for a different use.
Marketing frames sermorelin as a “natural” anti-aging GH booster with FDA pedigree. The pedigree is real — but it was earned in children with diagnosed deficiency and in diagnostic testing, not in healthy adults chasing body recomposition or longevity.
Most users are extrapolating a legitimate pituitary mechanism into territory that lacks modern controlled trials. The divergence is moderate rather than severe because the underlying biology is sound and the historical safety signal was benign; the honest gap is outcome data at wellness doses.
Most users are extrapolating a legitimate pituitary mechanism into territory that lacks modern controlled trials. The divergence is moderate rather than severe because the underlying biology is sound and the historical safety signal was benign; the honest gap is outcome data at wellness doses.
Dose Reference
Not medical advice. Not instruction for human use. For reference only.
Legacy therapeutic (Geref)
Weight-based
historical pediatric GHD dosing, physician-directed
Common compounded
~200–500 mcg
subcutaneous, once nightly (reported)
Timing
Bedtime
aligns with nocturnal GH pulse; empty stomach
Route
Subcutaneous
short half-life favors daily use
Figures reflect historical labeling and commonly reported compounded practice, not a recommendation. There is no standardized, regulator-sanctioned adult wellness dose. Compounded product potency and purity vary.
Safety Profile
Sermorelin’s historical safety profile, from supervised pediatric and diagnostic use, was generally favorable — a point in its favor relative to newer, untested peptides. That record does not automatically transfer to unsupervised adult use of compounded material.
Animal / preclinical — signals observed
Injection-site reactions (redness, pain, swelling)
Flushing, headache, or dizziness
Occasional nausea or altered taste
Rare hypersensitivity reactions
What is not known (human)
Long-term effects of chronic use in healthy adults
Consequences of sustained IGF-1 elevation over years
Interactions with thyroid, glucose, and other endocrine axes at wellness doses
Purity, sterility, and dosing accuracy of gray-market RUO product
Effects in people with undiagnosed proliferative or neoplastic conditions
Because it stimulates the body’s own GH within feedback limits, sermorelin is often described as lower-risk than direct GH — but “lower-risk” is not “no-risk,” and compounded supply adds its own uncertainties.
Regulatory Status — Updated July 2026
A real FDA history, no longer on the market
As Geref, sermorelin was FDA-approved for the diagnosis and treatment of growth-hormone deficiency in children. The manufacturer voluntarily discontinued it from the US market (around 2008) for commercial and manufacturing reasons — not for safety or efficacy. It is not currently an FDA-marketed drug, but remains available through compounding pharmacies, and is sold RUO in the research-chemical market. Sermorelin was not part of the July 23–24, 2026 PCAC meeting. Track current status →
Where to Source
Source research-grade Sermorelin
Lone Star Peptide Co. — Houston, TX. Batch-specific COAs on every vial, same-day domestic shipping, and third-party testing. The most transparent way to source Sermorelin.
Peptide Atlas is created by Lone Star Peptide Co. — a disclosed placement. Full disclosure.
Frequently Asked Questions
Yes. Under the brand name Geref it was FDA-approved for both the diagnosis and treatment of growth-hormone deficiency in children. This genuine regulatory history separates sermorelin from most peptides that have never seen an approval.
The manufacturer voluntarily withdrew Geref from the US market (around 2008) for commercial and manufacturing reasons, not because of safety problems or a finding that it did not work. Discontinuation here reflects business decisions, not a recall.
No. Sermorelin was not on the agenda for the July 23–24, 2026 PCAC meeting and was not reviewed or voted on. Any claim tying it to that review is inaccurate.
No. The strong human data are in pediatric GH deficiency and diagnostic testing. Adult anti-aging and body-composition claims rest largely on mechanism and extrapolation, with limited modern controlled trials at the doses people actually use.
Compare Sermorelin